Asia Pacific Journal of Clinical Trials: Nervous System Diseases

CORRESPONDENCE
Year
: 2016  |  Volume : 1  |  Issue : 3  |  Page : 149--151

Seven alternative opportunities to overcome the «DQ»Valley of Death«DQ» for CNS drug candidates developed by academic researchers


Pierre Guertin 
 Department of Psychiatry and Neurosciences, Faculty of Medicine, Laval University, Quebec City, QC; Nordic Life Science Pipeline Inc., Quebec City, QC, Canada

Correspondence Address:
Pierre Guertin
Department of Psychiatry and Neurosciences, Faculty of Medicine, Laval University, Quebec City, QC; Nordic Life Science Pipeline Inc., Quebec City, QC
Canada

The pharmaceutical industry has been facing tremendous challenges in recent years. Its Research & Development activities for innovation and drug development have significantly slowed down. Researchers in academic institutions often collaborate with pharmaceutical companies by providing them with new innovative products. However, the type of funding that they normally have access to does not ease drug development beyond discovery level. Here is a list of seven alternative opportunities that may help scientists, in North America, Europe and Asia, developing further their products and overcoming the so-called «DQ»Valley of Death«DQ». This may contribute bridging the gap between them and what Big Pharma is looking for, especially for the development of central nervous system products.


How to cite this article:
Guertin P. Seven alternative opportunities to overcome the "Valley of Death" for CNS drug candidates developed by academic researchers.Asia Pac J Clin Trials Nerv Syst Dis 2016;1:149-151


How to cite this URL:
Guertin P. Seven alternative opportunities to overcome the "Valley of Death" for CNS drug candidates developed by academic researchers. Asia Pac J Clin Trials Nerv Syst Dis [serial online] 2016 [cited 2019 Dec 13 ];1:149-151
Available from: http://www.actnjournal.com/article.asp?issn=2542-3932;year=2016;volume=1;issue=3;spage=149;epage=151;aulast=Guertin;type=0